The 5 most recent market catalysts affecting $STRO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 55
Citizens Maintains Market Outperform on Sutro Biopharma, Lowers Price Target to $34
Citizens analyst Reni J. Benjamin maintained a 'Market Outperform' rating on Sutro Biopharma (STRO), signaling continued confidence in the company's fundamentals and future perform…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 55
Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target
This 8-K filing discloses that Wedbush analyst David Nierengarten has reiterated an 'Outperform' rating and maintained a $60 price target for Sutro Biopharma (STRO). This action si…
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 85
Sutro Biopharma shares are trading lower after the company reported worse-than-expected Q2 financial results.
This headline represents a significant corporate catalyst for Sutro Biopharma. Worse-than-expected financial results often lead to immediate stock price depreciation as investors a…
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 92
Sutro Biopharma Q2 EPS $(2.33) Misses $(2.19) Estimate, Sales $9.839M Miss $13.048M Estimate
Sutro Biopharma's Q2 earnings report revealed a loss per share of $(2.33), missing analyst estimates by 6.39%, and sales of $9.839 million, missing estimates by 24.60%. This repres…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.